Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.
The uptake of NM394, a new quinolone, by and its subsequent elution from human polymorphonuclear leukocytes were studied and compared with those of ofloxacin and ciprofloxacin. The kinetics of the uptake of NM394 was similar to that of ciprofloxacin. The maximum intracellular-to-extracellular concentration ratio was 12.3, compared with 8.6 for ciprofloxacin and 4.9 for ofloxacin at the extracellular concentration of 20 micrograms/ml. The elution of NM394 from human polymorphonuclear leukocytes occurs relatively slowly; 5 min after the removal of extracellular NM394, nearly 100% still remained in polymorphonuclear leukocytes, compared with ofloxacin, which was so rapidly eluted that only 12% remained. The uptake of NM394 was significantly decreased at 4 degrees C and by the presence of NaCN but was not affected by the presence of L-glycine, L-leucine, L-serine, adenosine, or NaF. NM394 showed intracellular activity at a concentration of 0.1 microgram/ml that significantly reduced the number of phagocytosed Pseudomonas aeruginosa cells with 2 h of incubation. These results suggest that uptake of NM394 by human polymorphonuclear leukocytes occurs via an active transport system differing from that of ofloxacin, whose uptake is affected by the presence of L-glycine and L-leucine, and that once accumulated, NM394 remains intracellularly active and participates in protection against bacterial infection.
Ozaki
M
M
Discovery Research Laboratories II, Nippon Shinyaku Co., Ltd., Kyoto, Japan.
Komori
K
K
Matsuda
M
M
Yamaguchi
R
R
Honmura
T
T
Tomii
Y
Y
Nishimura
I
I
Nishino
T
T
D000596:Amino Acids / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000378:metabolism* / Q000494:pharmacology*; D000963:Antimetabolites / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism* / Q000382:microbiology*; D009696:Nucleic Acids / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects; D010879:Piperazines / Q000378:metabolism* / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D015363:Quinolones / Q000378:metabolism* / Q000494:pharmacology*
D000596:Amino Acids; D000890:Anti-Infective Agents; D000963:Antimetabolites; D024841:Fluoroquinolones; D009696:Nucleic Acids; D010879:Piperazines; D015363:Quinolones; D002939:Ciprofloxacin; D015242:Ofloxacin; C074190:ulifloxacin